Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000180427 | SCV000232860 | uncertain significance | not provided | 2014-12-12 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001852247 | SCV002247544 | likely benign | RYR1-related disorder | 2024-10-17 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002500520 | SCV002813360 | uncertain significance | Central core myopathy; Malignant hyperthermia, susceptibility to, 1; Congenital multicore myopathy with external ophthalmoplegia; Congenital myopathy with fiber type disproportion; King Denborough syndrome | 2021-10-19 | criteria provided, single submitter | clinical testing | |
All of Us Research Program, |
RCV003996587 | SCV004819823 | likely benign | Malignant hyperthermia, susceptibility to, 1 | 2023-11-30 | criteria provided, single submitter | clinical testing | This variant is located in the RYR1 protein. To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with RYR1-related disorders in the literature. This variant has been identified in 5/251404 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004586602 | SCV005076816 | likely benign | not specified | 2024-04-09 | criteria provided, single submitter | clinical testing |